37 results about "Plasmalogen" patented technology

The invention provides novel, simple, reliable and effective methods for separating various lipids from biological samples. In certain embodiments, the invention provides HILIC-based UHPLC separation methods. In one embodiment, the methods of the invention offer an efficient and rapid separation of ether glycophospholipids (e.g., plasmalogens) from their diacyl or monoacyl counterparts within the same lipid class. In certain instances, the invention relates to the use of a Waters ACQUITY UPLC® system.

The invention discloses a method of extracting plasmalogen of hyriopsis cumingii by using a titanium-based mesoporous silica gel composite material. The method comprises the following steps: extracting coarse lipid from hyriopsis cumingii powder A1; carrying out an alkaline reaction on the obtained lipid coarse extract to obtain an alkaline reactant C1; preparing the titanium-based mesoporous silica gel composite material; and filling a chromatographic column with the titanium-based mesoporous silica gel composite material, adding the alkaline reactant C1 into the chromatographic column, eluting the chromatographic column with an organic solvent, collecting an eluent and drying the eluent to obtain plasmalogen. The extraction method has the characteristics of being high in plasmalogen yield and good in product quality, utilizing waste resources and facilitating environmental protection.

The present invention relates generally to compounds such as alkylglycerol and alkoxyglycerol for use in increasing the endogenous level of plasmalogens in a mammal. In particular, these compounds are used for increasing the endogenous plasmalogen level to a level greater than the level in healthy mammals. According to the present invention such compounds are also for use in the prevention or treatment of diseases caused or affected by a decreased endogenous level of plasmalogens. A method for the manufacture of a dietary precursor for the use of the present invention is also part of the present disclosure.

Disclosed is a process for producing sphingomyelin and plasmalogen-form glycerophospholipid, which comprises the step (A) of extracting a total lipids from a chicken skin powder and drying the extract, the step (B) of subjecting the dried total lipids obtained in said step (A), to extraction treatment with a solvent mixture of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent to separate an insoluble portion composed mainly of sphingomyelin and a soluble portion, the step (C) subjecting the insoluble portion composed mainly of sphingomyelin, obtained in said step (B), to extraction treatment with a solvent mixture of water and a water-soluble ketone solvent to remove a non-lipid component contained in the soluble portion, and the step (D) of drying the soluble portion obtained in said step (B), and subjecting the thus-obtained dried product to extraction treatment with a water-soluble ketone solvent to separate and recover an insoluble portion composed mainly of plasmalogen-form giycerophospholiuld.According to the above production process, high-purity sphingomyelin, in particular, human-form sphingomyelin and plasmalogen-form sphingomyelin can be produced from chicken skin at high yields with simple procedures.

The invention provides a preparation method and application of eicosapentaenoic acid (EPA) plasmalogen. According to the preparation method, the EPA plasmalogen is prepared by extracting from sea cucumber, and experiments prove that the EPA plasmalogen of all components has an improvement effect on atherosclerosis. The EPA plasmalogen is prepared by taking the sea cucumber as a raw material, and then separating the components; and the purities of the obtained pPC and pPE are 90% or above. The animal experiments prove that the EPA plasmalogen of all the components can effectively reduce the area of atherosclerotic plaque, that is, the EPA plasmalogen can significantly inhibit the development of atherosclerosis, showing that the EPA plasmalogen can effectively prevent, ameliorate or treat the atherosclerosis.

The invention discloses the application of a microbial source plasmalogen in the treatment of colon cancer, and belongs to the technical field of biomedicine and microbes. In order to provide a method for improving colon cancer. The present invention provides the application of a kind of microbial source plasmalogen in the preparation and treatment of colon cancer. extracted from a mixture. Microbial plasmalogens can reduce the expression of colon cancer-related cytokines at the molecular level, inhibit the proliferation of colon cancer cells, reduce the number and volume of colon adenomas in patients with colon cancer, and can be used as an effective nutrient for the prevention and treatment of colon cancer strategy to provide theoretical support for the efficient utilization of plasmalogen derived from gut microbes.

The invention belongs to the technical field of active substance screening, and relates to a preparation method and application of EPA / ARA type plasmalogens. Continuous hydrolysis of phospholipid complexes with PLA1 enzyme followed by supercritical CO 2 Fluid extraction technology extracts EPA / ARA plasmalogen from enzymatic phospholipids. The EPA / ARA type plasmalogen prepared by the present invention has a purity of more than 80%, and compared with the EPA type plasmalogen or the ARA type plasmalogen, it can significantly reduce the behavioral cognitive function of Alzheimer's disease mice , improving brain Aβ aggregation and Tau protein aggregation, can be used to prepare drugs for preventing and treating diseases such as Alzheimer's disease, and has broad market application prospects.